Fairvalue-Calculator Fairvalue-Calculator
EN DE

Nanexa AB (NANEXA) Fair Value & Analysis

Healthcare · SE · Market cap 793M SEK

Pricekr 3.57
Fair Valuekr 2.47
Upside-30.7%
Quality95/100
Evidence: Low Range kr 1.85 – kr 3.09

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Nanexa AB (NANEXA) currently trades at kr 3.57, while our model-based Fair Value estimate is kr 2.47 — implying the stock looks roughly 30.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, a drug from lenalidomide for the treatment of multiple myeloma. The company has collaborations with Novo Nordisk to evaluate PharmaShell technology; and Moderna for the development of pharmaceutical products with active substances. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Nanexa AB (NANEXA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 2.47 versus a price of kr 3.57 — about −31% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NANEXA?
Our 21-model fair value for Nanexa AB is kr 2.47 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 3.57.
What is the quality score of NANEXA?
Nanexa AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.